Clinical application of stem cell therapy in Parkinson's disease
Top Cited Papers
Open Access
- 4 January 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in BMC Medicine
- Vol. 10 (1), 1
- https://doi.org/10.1186/1741-7015-10-1
Abstract
Cell replacement therapies in Parkinson's disease (PD) aim to provide long-lasting relief of patients' symptoms. Previous clinical trials using transplantation of human fetal ventral mesencephalic (hfVM) tissue in the striata of PD patients have provided proof-of-principle that such grafts can restore striatal dopaminergic (DA-ergic) function. The transplants survive, reinnervate the striatum, and generate adequate symptomatic relief in some patients for more than a decade following operation. However, the initial clinical trials lacked homogeneity of outcomes and were hindered by the development of troublesome graft-induced dyskinesias in a subgroup of patients. Although recent knowledge has provided insights for overcoming these obstacles, it is unlikely that transplantation of hfVM tissue will become routine treatment for PD owing to problems with tissue availability and standardization of the grafts. The main focus now is on producing DA-ergic neuroblasts for transplantation from stem cells (SCs). There is a range of emerging sources of SCs for generating a DA-ergic fate in vitro. However, the translation of these efforts in vivo currently lacks efficacy and sustainability. A successful, clinically competitive SC therapy in PD needs to produce long-lasting symptomatic relief without side effects while counteracting PD progression.This publication has 60 references indexed in Scilit:
- Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian ratsProceedings of the National Academy of Sciences of the United States of America, 2010
- Efficient Generation of Functional Dopaminergic Neurons from Human Induced Pluripotent Stem Cells Under Defined ConditionsThe International Journal of Cell Cloning, 2010
- Direct conversion of fibroblasts to functional neurons by defined factorsNature, 2010
- Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming FactorsCell, 2009
- Disease-Specific Induced Pluripotent Stem CellsCell, 2008
- Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's diseaseProceedings of the National Academy of Sciences of the United States of America, 2008
- Therapeutic cloning in individual parkinsonian miceNature Medicine, 2008
- Highly efficient and large-scale generation of functional dopamine neurons from human embryonic stem cellsProceedings of the National Academy of Sciences of the United States of America, 2008
- Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cellsProceedings of the National Academy of Sciences of the United States of America, 2007
- Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined FactorsCell, 2006